Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Kabi AG

www.fresenius-kabi.com

Latest From Fresenius Kabi AG

Special Counsel Finds US FDA’s Dismissal Of Inspection Concerns Unreasonable

Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.

Quality Compliance

Fresenius Kabi Launches First US Foscavir Rival

Fresenius Kabi has launched the first-ever generic version of Pfizer’s Foscavir in the US, with the product available immediately.

Generic Drugs Launches

Roche’s Actemra Scores New Indication In Rare Autoimmune Disease

The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.

Commercial Business Strategies

Fresenius Kabi: No Launches From US Melrose Park Facility In 2021

Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.

Manufacturing FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
UsernamePublicRestriction

Register